米索硝唑在人体肿瘤组织和正常组织中的分布。
Distribution of misonidazole in human tumours and normal tissues.
作者信息
Ash D V, Smith M R, Bugden R D
出版信息
Br J Cancer. 1979 May;39(5):503-9. doi: 10.1038/bjc.1979.93.
Abstract
Levels of misonidazole in human tumours, normal tissues and blood have been measured in patients given a 1g oral dose of drug before surgery or biopsy. The results show that 50--70% of the blood level was found in a wide range of tumours and that similar levels were found in adjacent normal tissues. Good penetration of drug was achieved within tumours, and up to 90--100% of the blood level was found in the necrotic cyst fluid at the centre of some tumours. CSF studies showed free diffusion into the CNS, which was confirmed by finding 50--70% of the blood level within brain tumours. A delay of passage of drugs into the CSF was noted, which was not found for drug diffusion into bile and saliva.
摘要
在手术或活检前给予口服1g米索硝唑的患者中，已测量了人肿瘤、正常组织和血液中的米索硝唑水平。结果显示，在多种肿瘤中发现了50%-70%的血药浓度，且在相邻正常组织中也发现了类似浓度。药物在肿瘤内实现了良好的渗透，在一些肿瘤中心的坏死囊液中发现了高达90%-100%的血药浓度。脑脊液研究显示药物可自由扩散至中枢神经系统，这通过在脑肿瘤中发现50%-70%的血药浓度得到证实。注意到药物进入脑脊液存在延迟，而药物扩散至胆汁和唾液中未发现这种情况。
相似文献
1
Distribution of misonidazole in human tumours and normal tissues.米索硝唑在人体肿瘤组织和正常组织中的分布。
Br J Cancer. 1979 May;39(5):503-9. doi: 10.1038/bjc.1979.93.
2
The penetration of misonidazole and desmethylmisonidazole into brain tumours and other central nervous system tissues in man.米索硝唑和去甲基米索硝唑在人体脑肿瘤及其他中枢神经系统组织中的渗透情况。
Br J Radiol. 1983 Nov;56(671):859-63. doi: 10.1259/0007-1285-56-671-859.
3
Causes of apparent low levels of misonidazole in human tumours.人肿瘤中米索硝唑水平明显较低的原因。
Clin Radiol. 1980 Mar;31(2):233-7. doi: 10.1016/s0009-9260(80)80172-3.
4
The concentration of desmethylmisonidazole in human tumours and in cerebrospinal fluid.去甲基米索硝唑在人体肿瘤组织和脑脊液中的浓度。
Br J Cancer. 1981 Mar;43(3):344-9. doi: 10.1038/bjc.1981.54.
5
Systemic, bladder wall, and bladder tumor concentration of misonidazole following intravesical administration in the rat.大鼠膀胱内给药后米索硝唑的全身、膀胱壁及膀胱肿瘤浓度
Int J Radiat Oncol Biol Phys. 1983 Sep;9(9):1397-400. doi: 10.1016/0360-3016(83)90273-0.
6
7
The labelling of EMT-6 tumours in BALB/C mice with 14C-misonidazole.用¹⁴C-米索硝唑对BALB/C小鼠的EMT-6肿瘤进行标记。
Br J Radiol. 1983 Oct;56(670):745-53. doi: 10.1259/0007-1285-56-670-745.
8
The penetration of misonidazole into spontaneous canine tumours.米索硝唑在犬自发性肿瘤中的渗透情况。
Br J Cancer. 1979 Aug;40(2):284-94. doi: 10.1038/bjc.1979.177.
9
Kinetic aspects of misonidazole and its major metabolite in radiotherapy.米索硝唑及其主要代谢物在放射治疗中的动力学研究
Hum Toxicol. 1985 Jul;4(4):425-34. doi: 10.1177/096032718500400409.
10
Pharmacokinetic considerations of misonidazole in therapeutics.米索硝唑在治疗学中的药代动力学考量。
Hum Toxicol. 1984 Feb;3(1):29-36. doi: 10.1177/0960327184003001041.
引用本文的文献
1
Mitochondrial alterations produced by misonidazole: a study using Amoeba proteus as a single-cell model.米索硝唑引起的线粒体改变：以大变形虫为单细胞模型的研究
Br J Cancer. 1980 Feb;41(2):305-8. doi: 10.1038/bjc.1980.44.
2
Phenytoin shortens the half-life of the hypoxic cell radiosensitizer misonidazole in man: implications for possible reduced toxicity.苯妥英钠可缩短人体中缺氧细胞放射增敏剂米索硝唑的半衰期：对可能降低毒性的意义。
Br J Cancer. 1980 Feb;41(2):302-4. doi: 10.1038/bjc.1980.43.
3
Pharmacokinetic and tumour-penetration properties of the hypoxic cell radiosensitizer desmethylmisonidazole (Ro 05-Ro-9963) in dogs.乏氧细胞放射增敏剂去甲基米索硝唑（Ro 05-Ro-9963）在犬体内的药代动力学及肿瘤穿透特性
Br J Cancer. 1980 Feb;41(2):268-76. doi: 10.1038/bjc.1980.39.
4
Phenytoin-induced changes in the pharmacokinetics of misonidazole in radiotherapy patients.苯妥英钠对放疗患者米索硝唑药代动力学的影响。
Br J Cancer. 1981 Oct;44(4):592-6. doi: 10.1038/bjc.1981.232.
5
Transition from laboratory to clinic in cancer treatment. Abstracts of symposium papers.癌症治疗从实验室到临床的转变。研讨会论文摘要。
Br J Cancer. 1981 May;43(5):701-35. doi: 10.1038/bjc.1981.102.
6
The concentration of desmethylmisonidazole in human tumours and in cerebrospinal fluid.去甲基米索硝唑在人体肿瘤组织和脑脊液中的浓度。
Br J Cancer. 1981 Mar;43(3):344-9. doi: 10.1038/bjc.1981.54.
7
Combination studies with misonidazole and a cis-platinum complex: cytotoxicity and radiosensitization in vitro.米索硝唑与顺铂复合物的联合研究：体外细胞毒性和放射增敏作用
Br J Cancer. 1980 Apr;41(4):517-22. doi: 10.1038/bjc.1980.93.
8
Absorption and distribution of vaginally administered misonidazole.阴道给药米索硝唑的吸收与分布。
Cancer Chemother Pharmacol. 1982;9(2):118-9. doi: 10.1007/BF00265391.
9
The penetration of misonidazole into a mature structural cartilage.米索硝唑在成熟结构软骨中的渗透情况。
Br J Cancer. 1982 Feb;45(2):282-5. doi: 10.1038/bjc.1982.44.
10
A randomized study of misonidazole and radiotherapy for grade 3 and 4 cerebral astrocytoma.米索硝唑与放疗治疗3级和4级脑星形细胞瘤的随机研究。
Br J Cancer. 1981 Apr;43(4):436-42. doi: 10.1038/bjc.1981.64.
本文引用的文献
1
Clinical phase I study of the hypoxic cell radiosensitizer RO-07-0582, a 2-nitroimidazole derivative.2-硝基咪唑衍生物低氧细胞放射增敏剂RO-07-0582的临床I期研究
Radiology. 1977 Mar;122(3):801-4. doi: 10.1148/122.3.801.
2
Clinical testing of the radiosensitiser Ro-07-0582. I. Dose tolerance, serum and tumour concentrations.放射增敏剂Ro-07-0582的临床试验。I. 剂量耐受性、血清和肿瘤浓度。
Clin Radiol. 1976 Apr;27(2):151-7. doi: 10.1016/s0009-9260(76)80137-7.
3
Estimation of the hypoxic cell-sensitiser misonidazole and its O-demethylated metabolite in biological materials by reversed-phase high-performance liquid chromatography.采用反相高效液相色谱法测定生物材料中乏氧细胞增敏剂米索硝唑及其O-去甲基代谢物。
J Chromatogr. 1978 May 1;145(3):507-12. doi: 10.1016/s0378-4347(00)81386-9.
4
Distribution and tumour cytotoxicity of the radiosensitizer misonidazole (Ro-07-0582) in C57 mice.放射增敏剂米索硝唑（Ro-07-0582）在C57小鼠体内的分布及肿瘤细胞毒性
Br J Cancer. 1979 Apr;39(4):429-33. doi: 10.1038/bjc.1979.76.
Zotero 插件